Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing
The emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants is associated with accelerated disease progression. CXCR4-using variants are believed to evolve from CCR5-using variants, but due to the extremely low frequency at which transitional intermediate variants are often present, the kinetics and mutational pathways involved in this process have been difficult to study and are therefore poorly understood. Here, we used ultra-deep sequencing of the V3 loop of the viral envelope in combination with the V3-based coreceptor prediction tools PSSMNSI/SI and geno2pheno[coreceptor] to detect HIV-1 variants during the transition from CCR5- to CXCR4-usage. We analyzed PBMC and serum samples obtained from eight HIV-1-infected individuals at three-month intervals up to one year prior to the first phenotypic detection of CXCR4-using variants in the MT-2 assay. Between 3,482 and 10,521 reads were generated from each sample. In all individuals, V3 sequences of predicted CXCR4-using HIV-1 were detected at least three months prior to phenotypic detection of CXCR4-using variants in the MT-2 assay. Subsequent analysis of the genetic relationships of these V3 sequences using minimum spanning trees revealed that the transition in coreceptor usage followed a stepwise mutational pathway involving sequential intermediate variants, which were generally present at relatively low frequencies compared to the major predicted CCR5- and CXCR4-using variants. In addition, we observed differences between individuals with respect to the number of predicted CXCR4-using variants, the diversity among major predicted CCR5-using variants, and the presence or absence of intermediate variants with discordant phenotype predictions. These results provide the first detailed description of the mutational pathways in V3 during the transition from CCR5- to CXCR4-usage in natural HIV-1 infection.
Vyšlo v časopise:
Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing. PLoS Pathog 7(6): e32767. doi:10.1371/journal.ppat.1002106
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002106
Souhrn
The emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants is associated with accelerated disease progression. CXCR4-using variants are believed to evolve from CCR5-using variants, but due to the extremely low frequency at which transitional intermediate variants are often present, the kinetics and mutational pathways involved in this process have been difficult to study and are therefore poorly understood. Here, we used ultra-deep sequencing of the V3 loop of the viral envelope in combination with the V3-based coreceptor prediction tools PSSMNSI/SI and geno2pheno[coreceptor] to detect HIV-1 variants during the transition from CCR5- to CXCR4-usage. We analyzed PBMC and serum samples obtained from eight HIV-1-infected individuals at three-month intervals up to one year prior to the first phenotypic detection of CXCR4-using variants in the MT-2 assay. Between 3,482 and 10,521 reads were generated from each sample. In all individuals, V3 sequences of predicted CXCR4-using HIV-1 were detected at least three months prior to phenotypic detection of CXCR4-using variants in the MT-2 assay. Subsequent analysis of the genetic relationships of these V3 sequences using minimum spanning trees revealed that the transition in coreceptor usage followed a stepwise mutational pathway involving sequential intermediate variants, which were generally present at relatively low frequencies compared to the major predicted CCR5- and CXCR4-using variants. In addition, we observed differences between individuals with respect to the number of predicted CXCR4-using variants, the diversity among major predicted CCR5-using variants, and the presence or absence of intermediate variants with discordant phenotype predictions. These results provide the first detailed description of the mutational pathways in V3 during the transition from CCR5- to CXCR4-usage in natural HIV-1 infection.
Zdroje
1. ZhuTMoHWangNNamDSCaoY 1993 Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261 1179 1181
2. Van 't WoutABKootstraNAMulder-KampingaGAbrecht-vanLNScherpbierHJ 1994 Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 94 2060 2067
3. KeeleBFGiorgiEESalazar-GonzalezJFDeckerJMPhamKT 2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105 7552 7557
4. Salazar-GonzalezJFSalazarMGKeeleBFLearnGHGiorgiEE 2009 Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206 1273 1289
5. SchuitemakerHKootMKootstraNADercksenMWDe GoedeREY 1992 Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 66 1354 1360
6. KootMKeetIPMVosAHVDe GoedeREYRoosMThL 1993 Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118 681 688
7. RichmanDDBozzetteSA 1994 The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169 968 974
8. ConnorRISheridanKECeradiniDChoeSLandauNR 1997 Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185 621 628
9. HuangWEshlemanSHTomaJFransenSStawiskiE 2007 Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 81 7885 7893
10. KootMVan 't WoutABKootstraNAde GoedeRETersmetteM 1996 Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 173 349 354
11. SchuitemakerHKootMKootstraNADercksenMWde GoedeRE 1992 Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66 1354 1360
12. O'BrienWAKoyanagiYNamazieAZhaoJQDiagneA 1990 HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348 69 73
13. ChesebroBNishioJPerrymanSCannAO'BrienW 1991 Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 65 5782 5789
14. ShiodaTLevyJACheng-MayerC 1992 Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89 9434 9438
15. GroeninkMFouchierRAMBroersenSBakerCHKootM 1993 Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260 1513 1516
16. FouchierRAMBroersenSMBrouwerMTersmetteMVan 't WoutAB 1995 Temporal relationship between elongation of the HIV-1 gp120 V2 domain and the conversion towards a syncytium inducing phenotype. AIDS Res Hum Retroviruses 11 1473 1478
17. PastoreCRamosAMosierDE 2004 Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 78 7565 7574
18. PastoreCNedellecRRamosAPontowSRatnerL 2006 Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 80 750 758
19. CarrilloARatnerL 1996 Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 70 1301 1309
20. HuangWTomaJFransenSStawiskiEReevesJD 2008 Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 82 5584 5593
21. FouchierRAMGroeninkMKootstraNATersmetteMHuismanHG 1992 Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66 3183 3187
22. De JongJJDe RondeAKeulenWTersmetteMGoudsmitJ 1992 Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66 6777 6780
23. BoydMTSimpsonGRCannAJJohnsonMAWeissRA 1993 A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 67 3649 3652
24. HarroweGCheng-MayerC 1995 Amino acid changes in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 210 490 494
25. KuikenCLDe JongJ-JBaanEKeulenWTersmetteM 1992 Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 66 4622 4627
26. Van 't WoutABBlaakHRanLJBrouwerMKuikenC 1998 Evolution of syncytium inducing and non-syncytium inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection. J Virol 72 5099 5107
27. KootMVosAHVKeetRPMDe GoedeREYDercksenW 1992 HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 6 49 54
28. JapourAJMayersDLJohnsonVAKuritzkesDRBeckettLA 1993 Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 37 1095 1101
29. WhitcombJMHuangWFransenSLimoliKTomaJ 2007 Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51 566 575
30. ReevesJDCoakleyEPetropolousCJWhitcombJM 2009 An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 3 94 102
31. ChesebroBWehrlyKNishioJPerrymanS 1996 Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 70 9055 9059
32. HungCSVanderHNRatnerL 1999 Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 73 8216 8226
33. JensenMALiFSVan 't WoutABNickleDCShrinerD 2003 Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77 13376 13388
34. LowAJDongWChanDSingTSwanstromR 2007 Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21 F17 F24
35. CoakleyEReevesJDHuangWMangas-RuizMMaurerI 2009 Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother 53 4686 4693
36. VerhofstedeCVandekerckhoveLEygenVVDemecheleerEVandenbrouckeI 2009 CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 50 126 136
37. Edo-MatasDvan GilsMJBowlesEJNavisMRachingerA 2010 Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405 492 504
38. GrahamRLHellP 1985 On the History of the Minimum Spanning Tree Problem. IEEE Ann Hist Comp 7 43 57
39. VauterinLVauterinP 2006 Integrated databasing and Analysis. StackebrandtE Molecular identification, systematics, and population structure of prokaryotes Heidelberg Springer 141 218
40. ShankarappaRMargolickJBGangeSJRodrigoAGUpchurchD 1999 Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73 10489 10502
41. RegoesRRBonhoefferS 2005 The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13 269 277
42. WestbyMLewisMWhitcombJYouleMPozniakAL 2006 Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80 4909 4920
43. FatkenheuerGNelsonMLazzarinAKonourinaIHoepelmanAI 2008 Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359 1442 1455
44. SuZGulickRMKrambrinkACoakleyEHughesMD 2009 Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 200 1724 1728
45. TsibrisAMKorberBArnaoutRRussCLoCC 2009 Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 4 e5683
46. AbbateIVlassiCRozeraGBrusellesABartoliniB 2011 Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 25 611 617
47. DorrPWestbyMDobbsSGriffinPIrvineB 2005 Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49 4721 4732
48. StrizkiJMTremblayCXuSWojcikLWagnerN 2005 Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 49 4911 4919
49. ArcherJBravermanMSTaillonBEDesanyBJamesI 2009 Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23 1209 1218
50. SwensonLCMooresALowAJThielenADongW 2010 Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA. J Acquir Immune Defic Syndr 54 506 510
51. BushmanFDHoffmannCRonenKMalaniNMinkahN 2008 Massively parallel pyrosequencing in HIV research. AIDS 22 1411 1415
52. HallTA 1999 BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41 95 98
53. SwoffordDL 2002 PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods), version 4 [computer program] Sunderland, Massachusetts Sinauer Associates
54. SaitouNNeiM 1987 The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4 406 425
55. HasegawaMKishinoHYanoT 1985 Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol 22 160 174
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 6
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- High Affinity Nanobodies against the VSG Are Potent Trypanolytic Agents that Block Endocytosis
- Structural and Mechanistic Studies of Measles Virus Illuminate Paramyxovirus Entry
- Sporangiospore Size Dimorphism Is Linked to Virulence of
- The Binding of Triclosan to SmeT, the Repressor of the Multidrug Efflux Pump SmeDEF, Induces Antibiotic Resistance in